CARG-2020

Mechanistically, CARG-2020 potently activates Th1 immune mechanisms and inhibits expression of genes related to T cell exhaustion and cancer-promoting inflammation. The ability of CARG-2020 to prevent tumor recurrence and to provide survival benefit makes it a promising candidate for its development for human cancer immunotherapy.

To achieve this, we developed CARG-2020, a genetically modified virus-like vesicle (VLV) that is a self-amplifying RNA with oncolytic capacity and encodes immune regulatory genes...Furthermore, we demonstrated that this therapeutic approach provided tumor-specific and long-term protection against the establishment of new tumors. Our results provide rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients to enhance anti-tumor responses and prevent recurrence.

We report the successful anti-tumoral effect of CARG-2020 by modulating the immune response in a syngeneic mouse model of recurrent ovarian cancer. CARG-2020, by enhancing the expression of IL-12 and blocking IL-17 and PD-L1, provided a long-term protection associated with the expansion of cytolytic effector memory CD8+T cells, which in addition to its antitumoral effect, provides protection against recurrent disease. Our results provide rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients.

CARG-2020 is able to prevent the establishment of recurrent disease in a syngeneic mouse model of recurrent ovarian cancer. Our results provide rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients.